DOCSLIB.ORG

AMRITA HOSPITALS AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AMRITA HOSPITALS AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR) AMRITA HOSPITALS HOSPITALS AMRITA AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR) A Comprehensive A Comprehensive Overview Overview A Comprehensive Overview AMRITA INSTITUTE OF MEDICAL SCIENCES AIMS Ponekkara P.O. Kochi, Kerala, India 682 041 Phone: (91) 484-2801234 Fax: (91) 484-2802020 email: [email protected] website: www.amritahospitals.org Copyright@2018 AMRITA HOSPITALS Kochi * Faridabad (Delhi-NCR) A COMPREHENSIVE OVERVIEW A Comprehensive Overview Copyright © 2018 by Amrita Institute of Medical Sciences All rights reserved. No portion of this book, except for brief review, may be reproduced, stored in a retrieval system, or transmitted in any form or by any means —electronic, mechanical, photocopying, recording, or otherwise without permission of the publisher. Published by: Amrita Vishwa Vidyapeetham Amrita Institute of Medical Sciences AIMS Ponekkara P.O. Kochi, Kerala 682041 India Phone: (91) 484-2801234 Fax: (91) 484-2802020 email: [email protected] website: www.amritahospitals.org June 2018 2018 ISBN 1-879410-38-9 Amrita Institute of Medical Sciences and Research Center Kochi, Kerala INDIA AMRITA HOSPITALS KOCHI * FARIDABAD (DELHI-NCR) A COMPREHENSIVE OVERVIEW 2018 Amrita Institute of Medical Sciences and Research Center Kochi, Kerala INDIA CONTENTS Mission Statement ......................................... 04 Message From The Director ......................... 05 Our Founder and Inspiration Sri Mata Amritanandamayi Devi .................. 06 Awards and Accreditations .......................... 07 Centers and Specialty Departments ............ 08 Center For Heart Diseases ............................ 10 Cancer Center ................................................. 34 Cyberknife ....................................................... 40 Tomotherapy .................................................. 41 Center For Digestive Diseases ...................... 51 da Vinci Robotic Surgical System ................. 56 Center For Neurosciences ............................ 61 ROSA Robotic Surgical Assistant .................. 69 Center For Endocrinology & Diabetes ......... 78 Center For Orthopedics ................................ 82 Mako Robotic Arm Assistant ....................... 83 Center For Plastic & Reconstructive Surgery ................................. 88 Center For Psychiatry & Clinical Psychology ......................................... 92 Center Of Excellence In Pediatric Genetics ......................................... 146 Organ Transplantation ................................ 96 Pediatric Surgery ........................................... 149 Anesthesiology & Critical Care Medicine .. 111 Ophthalmology ............................................. 151 Dermatology ................................................. 115 Vitreo Retinal Surgery ................................... 154 Emergency Medicine ................................... 117 Physical Medicine & Rehabilitation ............. 157 ENT Otorhinolaryngology ........................... 119 Pulmonary Medicine ..................................... 158 Division Of Thyroid, Parathyroid, Rheumatology & Clinical Immunology ....... 162 & Breast Services ......................................... 123 Speech Pathology & Audiology ................... 163 Geriatrics ....................................................... 124 Stroke Medicine ............................................ 166 Integrated Medicine .................................... 126 Urology & Renal Transplantation ................ 168 Internal Medicine ......................................... 128 Amrita Clinical Laboratory Services ............ 173 Medical Physics ............................................ 129 Center For Digital Health (CDH) ................. 179 Nephrology ................................................... 130 Community Service Outreach Programs .. 181 Nuclear Medicine ......................................... 132 Amrita Centre For Nanosciences Medical Imaging Center .............................. 134 & Molecular Medicine (ACNSMM) ............... 185 Amrita Fertility Center ................................. 136 Amrita Hospital Information System .......... 187 Obstetrics & Gynecology ............................. 139 Amrita Hospital Faridabad ........................... 189 Fetal Medicine & Perinatology.................... 142 Amrita Vishwa Vidyapeetham ..................... 192 Neonatology ................................................. 143 Index ............................................................... 193 General Pediatrics ........................................ 145 MISSION STATEMENT AMRITA INSTITUTE OF MEDICAL SCIENCES AND RESEARCH CENTRE (Amrita) is a not-for-profit organization dedicated to establishing a center of healthcare excellence and improving the well-being of the community through quality programs of preventive medicine, medical education, and research. We are committed to providing outstanding and affordable medical care in a patient-friendly environment and in a spirit of compassion to all, regardless of race, caste, religion, or economic condition. We offer charitable care to the fullest extent possible for those in need. MESSAGE FROM THE DIRECTOR ith our present healthcare operations spread Certified Services and a 24/7 telemedicine service. across Kerala, Karnataka, Maharashtra, Andaman Amrita features one of the most advanced hospital Wand Nicobar Islands, we soon stand to make our computer networks in India. The network supports presence felt in Faridabad (Delhi NCR). more than 2800 computers and has computerized Amrita Hospitals, with a total bed capacity of over 1100 nearly every aspect of patient care, including all beds, has treated more than 10 million (1 crore) patients patient information, lab testing and radiological across India. Charity Medical Care stands at a whopping imaging. US$ 110 million (Rs.700 crores) that has provided much The most recent additions are the DA VINCI needed free medical care to over 5 million (50 lakhs) SURGICAL ROBOTIC SYSTEM; ROSA, the latest deserving patients. generation in robotic neurosurgery assistance; the The Amrita healthcare system stands on an edifice MAKO ROBOTIC-ARM ASSISTED TECHNOLOGY which of sophisticated care being provided with love and is transforming the way joint replacement surgeries compassion. Today, Amrita Hospitals is recognized as one are being performed; a CYBERKNIFE M6 and of the premier healthcare institutions in South Asia. Our TOMOTHERAPY for the most precise radiotherapy commitment to affordable quality care has attracted a available today; the GE VOLUSON E10 4D ultrasound dedicated team of highly qualified medical professionals system for spectacular 2D and 3D/4D images; a from across the world. The Amrita team, comprised of Philips 256 slice iCT scanner; a PET-3TESLA MRI physicians, surgeons and other healthcare professionals, scanner which is extremely useful for early detection are of the highest caliber and experience. of cancer, and the Digital Pathology Solution, a virtual The massive healthcare infrastructure in Kochi, Kerala microscope which digitizes lab slides which more with over 3.33 million sq. ft. of built-up area, is spread accurately help clinicians in better, faster, cheaper over 125 acres of land. It supports a daily patient volume diagnosis and prediction of diseases. of approximately 3500 outpatients with 95 percent Amrita offers a total and comprehensive health inpatient occupancy. Annual patient turnover touches care solution comparable to the best hospitals in the an incredible figure of almost 1 million (10 lakhs) world. outpatients and nearly 50,000 inpatients. There are 12 super-specialty departments, 45 other departments, 4500 support staff and 670 faculty members. Sincerely, We have extensive facilities comprised of 28 modern Dr. Prem Nair operating theaters, 275 equipped intensive-care beds, a Medical Director fully computerized and networked Hospital Information Amrita Institute of Medical Sciences System (HIS), a fully digital radiology department, 17 Operating Officer, Health Sciences Campus NABL accredited clinical laboratories, NABH Accredited Amrita Vishwa Vidyapeetham Hospital Services, NAAC with “A Grade, ISO 9001:2008 OUR FOUNDER AND INSPIRATION SRI MATA AMRITANANDAMAYI DEVI “A LOVING SMILE, A KIND WORD, A DISPLAY OF GENUINE CONCERN BY MEDICAL PRACTITION ERS WILL DEFINITELY COMPLEMENT THE CURATIVE POWER OF THE MEDICINES.” Amma ove, compassion, empathy and tolerance— Amma had a vision of creating a hospital under the pressures of modern life, these in Kerala where the poor could receive Lqualities have all but disappeared. Through free advanced medical care, such as heart her loving embrace and charitable activities, Sri operations and kidney transplants, in an Mata Amritanandamayi Devi (affectionately known atmosphere of love and compassion. She saw as Amma or Mother) is healing the heart of the that while the poor did receive basic medical world, rekindling love and mutual respect, and care through various charitable clinics, awakening people to their fundamental oneness. advanced care was beyond their dreams. Through her extraordinary acts of love and This eventually led to the birth of the highly self-sacrifice, Amma has endeared herself to sophisticated, 1100-bed tertiary referral and millions. Tenderly caressing everyone who comes teaching Amrita Hospitals (Amrita). Amrita exemplifies Amma’s use of science and to her, holding them close to her heart in a loving technology
Load more

Recommended publications
  • Euro GTP Guidance
    EURO­GTP Euro GTP Guidance European Union Project in the framework of the Public Health Program Agreement number: 2007 207 Coordinator: Transplant Services Foundation 1 List of Authors ‐ Euro GTP Project Coordinator TSF ▪ Transplant Services Foundation | Spain Project Partners BISLIFE | Netherlands BTV ▪ Banca Tessuti della Regione Veneto | Italy CBC ▪ Hornhautbank Berlin Charite Universitatsmedizin | Germany EHB ▪ European Homograft Bank | Belgium ESB ▪ Euro Skin Bank | Netherlands HBM ▪ Hornhautbank München Gemeinnutzige | Germany ISS‐CNT ▪ Istituto Superiore di Sanita Centro Nazionale Trapianti | Italy KCBTiK ▪ Krajowe Centrum Bankowania Tkanek I Komórek | Poland QAMH ▪ Queen Astrid Military Hospital | Belgium REGEA ▪ Tampere Yliopisto. University of Tampere | Finland i Table of Contents PURPOSE AND SCOPE ................................................................................................................................................1 SECTION A: GENERAL REQUIREMENTS .......................................................................................................................3 A.1. PERSONNEL ............................................................................................................................................................... 3 A.2. FACILITIES AND EQUIPMENT ..................................................................................................................................... 8 A.2.1. FACILITIES, EQUIPMENT AND MATERIALS FOR RECOVERY...............................................................................
    [Show full text]
  • Ethical, Legal and Psychosocial Aspects of Transplantation Global Challenges
    E. K. Massey, F. Ambagtsheer, W. Weimar (Eds.) Ethical, Legal and Psychosocial Aspects of Transplantation Global Challenges PABST E. K. Massey, F. Ambagtsheer, W. Weimar (Eds.) Ethical, Legal and Psychosocial Aspects of Transplantation Global Challenges PABST SCIENCE PUBLISHERS Lengerich Bibliographic information published by Die Deutsche Nationalbibliothek Die Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.ddb.de>. This work is subject to copyright. All rights are reserved, whether the whole or part of the mate- rial is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a spe- cific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The authors and the publisher of this volume have taken care that the information and recommen- dations contained herein are accurate and compatible with the standards generally accepted at the time of publication. Nevertheless, it is difficult to ensure that all the information given is entirely accurate for all circumstances. The publisher disclaims any liability, loss, or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this volume. © 2017 Pabst Science Publishers · D-49525 Lengerich Internet: www.pabst-publishers.de, www.pabst-science-publishers.com E-mail: [email protected] Print: ISBN 978-3-95853-292-2 eBook: ISBN 978-3-95853-293-9 (www.ciando.com) Formatting: µ Printed in Germany by KM-Druck, D-64823 Gross-Umstadt Contents Preface Introduction Emma K.
    [Show full text]
  • Genitourinary Membership Requirements Workgroup Meeting Summary February 17, 2021 Conference Call
    OPTN Vascularized Composite Allograft Transplantation Committee Genitourinary Membership Requirements Workgroup Meeting Summary February 17, 2021 Conference Call Nicole M. Johnson, MBA, RN, Co-Chair Stefan Tullius, MD, PhD, Co-Chair Introduction The Vascularized Composite Allograft (VCA) Transplantation Committee’s Genitourinary Membership Requirements Workgroup met via Citrix GoTo teleconference on 02/17/2021 to discuss the following agenda items: 1. Primary Surgeon Requirements The following is a summary of the Workgroup’s discussions. 1. Primary Surgeon Requirements The Workgroup discussed requirements for the primary surgeon of a genitourinary organ VCA transplant program. Summary of discussion: Overview of Primary Surgeon Requirements for Upper Limb & Head and Neck Transplant Programs The primary surgeon requirements for upper limb and head and neck transplant programs have three main components: (1) general requirements regarding degree, licensure, and credentialing, as well as observation of multi-organ procurements; (2) board certification requirement, which can be met by American board certification or an alternative to American board certification; and (3) experience requirements, which can be met though completion of an Accreditation Council for Graduate Medical Education (ACGME) fellowship; completion of another fellowship that meets OPTN criteria; or a minimum clinical experience pathway. The Co-Chair noted that there is no ACGME fellowship specific to genitourinary organ transplants and asked if that means the primary surgeon for a genitourinary organ transplant program can only qualify via the clinical experience pathway. UNOS staff said that the Workgroup had previously identified some appropriate fellowships for the experience requirement but the Workgroup could also work on defining a clinical experience pathway. A member said that for organs that have a low case volume, like intestine and VCA, having parallel paths to qualify may be the best approach to help new programs get started.
    [Show full text]
  • Freezing of Surplus Donated Whole Eyes in the Central Eye Bank of Iran
    RESEARCH Freezing of Surplus Donated Whole Eyes in the Central Eye Bank of Iran Use of Defrosted Corneas for Deep Anterior Lamellar Keratoplasty and Report of Postoperative Eye Bank Data Mozhgan Rezaei Kanavi, MD; Mohammad Ali Javadi, MD; Fatemeh Javadi; Tahereh Chamani, MS ABSTRACT especially when a shortage exists for fresh donor corneas for transplantation. PURPOSE: To describe the method of freezing and thaw- KEYWORDS: cornea, freezing, whole eyes, DALK, ing of donated whole eyes (DWEs), which were surplus to eye banks, thawing....................................... requirements in the Central Eye Bank of Iran (CEBI), and to report the 3-year results of using defrosted corneas in deep anterior lamellar keratoplasty (DALK) in keratoconic eyes. he Central Eye Bank of Iran (CEBI) is the METHODS: The method of freezing and thawing of only eye bank in Iran and is located in Tehran. surplus DWEs in the CEBI is described. Surplus DWEs Tissue requirements for corneal and scleral at the CEBI were disinfected, processed, and transferred T transplantation in Iran are supplied and preserved to the freezer (-70°C) for long-term preservation. In case 1 of a shortage of fresh and refrigerated corneas for DALK, by the CEBI. There has been an increasing trend in a frozen DWE was defrosted and distributed for trans- corneal transplantation in Iran, from 200 grafts in plantation either as a whole eye in moist chamber or as 1988 to 6,053 in 2012 (unpublished data). Keratoco- an excised corneoscleral disc in Eusol C at 2˚C to 8˚C. nus is the most common indication for penetrating Furthermore, eye bank data of the frozen DWEs as well 1 as postoperative eye bank reports of implementation of keratoplasty in Iran, accounting for 34.5% of cases.
    [Show full text]
  • Transplantation and Hepatic Pathology University of Pittsburgh Medical Center November, 2007
    Resident Handbook Division of Transplantation and Hepatic Pathology University of Pittsburgh Medical Center November, 2007 For private use of residents only- not for public distribution Table of Contents Anatomic Transplantation Pathology Rotation Clinical Responsibilities of the Division ........................................................3 Categorizations of Specimens and Structure of Signout.................................3 Resident Responsibilities................................................................................4 Learning Resources.........................................................................................4 Transplantation Pathology on the World-Wide Web......................................4 Weekly Schedule ............................................................................................6 Staff Locations and Telephone Numbers........................................................7 Background Articles Landmarks in Transplantation ........................................................................8 Trends in Organ Donation and Transplantation US 1996-2005.....................18 Perspectives in Organ Preservation………....................................................26 Transplant Tolerance- Editorial……………………………………….…….36 Kidney Grading Systems Banff 2005 Update……………………….....................................................42 Banff 97 Components (I t v g etc.) ................................................................44 Readings Banff 05 Meeting Report………………………………………...................47
    [Show full text]
  • Four Cases of Corneal Perforation in Patients with Chronic Graft- Versus-Host Disease
    Molecular Vision 2011; 17:598-606 <http://www.molvis.org/molvis/v17/a68> © 2011 Molecular Vision Received 21 October 2010 | Accepted 15 February 2011 | Published 25 February 2011 Four cases of corneal perforation in patients with chronic graft- versus-host disease Emi Inagaki, Yoko Ogawa, Yukihiro Matsumoto, Tetsuya Kawakita, Shigeto Shimmura, Kazuo Tsubota Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan Purpose: To report the clinical features and investigate the underlying pathological processes of spontaneous corneal perforation in patients with ocular chronic graft-versus-host disease (cGVHD). Methods: A full ophthalmological evaluation of corneal perforation in four patients with cGVHD was performed. Three of them underwent deep anterior lamellar keratoplasty and samples from two of three patients were used for histopathological analyses. Results: Three patients were successfully treated by corneal transplantation. One patient was treated with a therapeutic soft contact lens, and the wound healed within 2 days. The common clinical features of these patients were (1) the presence of definite dry eye related to cGVHD in 3 of 4 patients and probable dry eye in one patient, (2) a central or paracentral site of corneal ulceration and perforation, with no sign of infection, and (3) prior use of a topical or systemic corticosteroid, and/or topical non-steroidal anti-inflammatory drugs. Immunohistochemical findings revealed an increased number of cluster of differentiation 68+ (CD68+) macrophages and matrix metalloproteinase 9 (MMP-9) expression in the tissue surrounding the perforation. Conclusions: Our report extends current information on the clinical features and pathological processes of corneal perforation in cGVHD by showing increased MMP-9 expression and the accumulation of CD68+ positive macrophages in the affected areas.
    [Show full text]
  • Msc Payment Schedule Index
    MSC PAYMENT SCHEDULE INDEX SECTIONS (To go directly to the an applicable section of the Payment Schedule, click on the Section heading listed below) GENERAL PREAMBLE TO THE PAYMENT SCHEDULE .................................. 1 2. OUT-OF-OFFICE HOURS PREMIUMS ............................................................... 2 3. GENERAL SERVICES ......................................................................................... 3 4. DIAGNOSTIC AND SELECTED THERAPEUTIC PROCEDURES ...................... 4 5. CRITICAL CARE .................................................................................................. 5 6. EMERGENCY MEDICINE .................................................................................... 6 7. GENERAL PRACTICE ......................................................................................... 7 8. ANESTHESIA ...................................................................................................... 8 9. DERMATOLOGY ................................................................................................. 9 10. OPHTHALMOLOGY .......................................................................................... 10 11. OTOLARYNGOLOGY ........................................................................................ 11 12. GENERAL INTERNAL MEDICINE .................................................................... 12 13. CARDIOLOGY ................................................................................................... 13 14. CLINICAL IMMUNOLOGY AND ALLERGY
    [Show full text]
  • Skin Grafts in Cutaneous Oncology* Enxertia De Pele Em Oncologia
    RevABDV81N5.qxd 07.11.06 17:07 Page 465 465 Artigo de Revisão Enxertia de pele em oncologia cutânea* Skin grafts in cutaneous oncology* José Anselmo Lofêgo Filho1 Paula Dadalti2 Diogo Cotrim de Souza3 Paulo Roberto Cotrim de Souza4 Marcos Aurélio Leiros da Silva5 Cristina Maeda Takiya6 Resumo: Em oncologia cutânea depara-se freqüentemente com situações em que a confec- ção de um enxerto é uma boa alternativa para o fechamento do defeito cirúrgico. Conhecer aspectos referentes à integração e contração dos enxertos é fundamental para que os cirur- giões dermatológicos procedam de maneira a não contrariar princípios básicos do trans- plante de pele. Os autores fazem uma revisão da classificação e fisiologia dos enxertos de pele, acrescendo considerações cirúrgicas determinantes para o sucesso do procedimento. Palavras-chave: Neoplasias cutâneas; Transplante de pele; Transplante homólogo Abstract: In cutaneous oncology, there are many situations in which skin grafts could be a good alternative for closing surgical defect. Dermatological surgeons should have enough knowledge about graft integration and contraction in order to not contradict the basic prin- ciples of skin transplantation. The authors review skin graft classification and physiology and make some surgical considerations on successful procedures. Keywords: Skin neoplasms; Skin transplantation; Transplantation, homologous INTRODUÇÃO Enxerto é parte de um tecido vivo transplanta- tológica. São simples quando apresentam um único do de um lugar para outro no mesmo organismo ou tipo de tecido e compostos quando constituídos de em organismos distintos.1 Contudo, a utilização da dois ou mais tipos de tecidos. Em oncologia cutânea, terminologia enxerto para designar uma modalidade um enxerto composto é usado quando o defeito cirúrgica, apesar de errônea, tornou-se coloquial.
    [Show full text]
  • Fast Facts & Stats
    FAST FACTS & STATS “Of all the senses, sight must be the most delightful.” ~ Helen Keller More sensory neurons are dedicated to vision than the other four senses combined, and giving the gift of sight – through cornea donation – can be life-giving and life-changing. But what does it really mean? “Eye donation” doesn’t mean the entire eye is transplanted; instead, only the cornea (the clear, dome-shaped surface that covers the front of the eye) is replaced, restoring sight for those with cornea-related blindness. The entire eye can be used for research and education, potentially helping untold thousands of people regain their sight as researchers gain new understanding of the cause and effects of eye conditions that lead to blindness. Historical facts: · The first human corneal transplant was performed in 1905 by Dr. Eduard Zirm in Olomouc, Czechoslovakia. · The first U.S. transplant was performed in New York City by Dr. R. Townley Paton in 1937. · The first eye bank – a non-profit organization that recovers, evaluates, prepares and distributes eyes donated for use in corneal transplantation, research and education – opened in 1944 in New York City. · The Eye Bank Association of America, established in 1961, is the oldest transplant association and was formed by a group of ophthalmologists and eye bankers. Statistics: · 50,930: Number of corneas provided for transplant in the U.S. in 2017, meeting 100% of U.S. demand. · 33,367: Number of corneas exported, helping restore sight worldwide. · 12 million: Corneal disease cases worldwide that result in blindness or visual impairment— and that could be reversed with cornea transplants.
    [Show full text]
  • 3Rd Quarter 2001 Bulletin
    In This Issue... Promoting Colorectal Cancer Screening Important Information and Documentaion on Promoting the Prevention of Colorectal Cancer ....................................................................................................... 9 Intestinal and Multi-Visceral Transplantation Coverage Guidelines and Requirements for Approval of Transplantation Facilities12 Expanded Coverage of Positron Emission Tomography Scans New HCPCS Codes and Coverage Guidelines Effective July 1, 2001 ..................... 14 Skilled Nursing Facility Consolidated Billing Clarification on HCPCS Coding Update and Part B Fee Schedule Services .......... 22 Final Medical Review Policies 29540, 33282, 67221, 70450, 76090, 76092, 82947, 86353, 93922, C1300, C1305, J0207, and J9293 ......................................................................................... 31 Outpatient Prospective Payment System Bulletin Devices Eligible for Transitional Pass-Through Payments, New Categories and Crosswalk C-codes to Be Used in Coding Devices Eligible for Transitional Pass-Through Payments ............................................................................................ 68 Features From the Medical Director 3 he Medicare A Bulletin Administrative 4 Tshould be shared with all General Information 5 health care practitioners and managerial members of the General Coverage 12 provider/supplier staff. Hospital Services 17 Publications issued after End Stage Renal Disease 19 October 1, 1997, are available at no-cost from our provider Skilled Nursing Facility
    [Show full text]
  • Exploring Vigilance Notification for Organs
    NOTIFY - E xploring V igilanc E n otification for o rgans , t issu E s and c E lls NOTIFY Exploring VigilancE notification for organs, tissuEs and cElls A Global Consultation e 10,00 Organised by CNT with the co-sponsorship of WHO and the participation of the EU-funded SOHO V&S Project February 7-9, 2011 NOTIFY Exploring VigilancE notification for organs, tissuEs and cElls A Global Consultation Organised by CNT with the co-sponsorship of WHO and the participation of the EU-funded SOHO V&S Project February 7-9, 2011 Cover Bologna, piazza del Nettuno (photo © giulianax – Fotolia.com) © Testi Centro Nazionale Trapianti © 2011 EDITRICE COMPOSITORI Via Stalingrado 97/2 - 40128 Bologna Tel. 051/3540111 - Fax 051/327877 [email protected] www.editricecompositori.it ISBN 978-88-7794-758-1 Index Part A Bologna Consultation Report ............................................................................................................................................7 Part B Working Group Didactic Papers ......................................................................................................................................57 (i) The Transmission of Infections ..........................................................................................................................59 (ii) The Transmission of Malignancies ....................................................................................................................79 (iii) Adverse Outcomes Associated with Characteristics, Handling and Clinical Errors
    [Show full text]
  • Xenotransplantation: Past, Present, and Future
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Curr Opin Manuscript Author Organ Transplant Manuscript Author . Author manuscript; available in PMC 2018 December 01. Published in final edited form as: Curr Opin Organ Transplant. 2017 December ; 22(6): 513–521. doi:10.1097/MOT.0000000000000463. XENOTRANSPLANTATION: PAST, PRESENT, AND FUTURE Burcin Ekser, MD, PhD1, Ping Li, PhD1, and David K.C. Cooper, MD, PhD2 1Division of Transplant Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA 2Xenotransplantation Program, Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL, USA Abstract Purpose of review—To review the progress in the field of xenotransplantation with special attention to most recent encouraging findings which will eventually bring xenotransplantation to the clinic in the near future. Recent findings—Starting from early 2000, with the introduction of Gal-knockout pigs, prolonged survival especially in heart and kidney xenotransplantation was recorded. However, remaining antibody barriers to nonGal antigens continue to be the hurdle to overcome. The production of genetically-engineered pigs was difficult requiring prolonged time. However, advances in gene editing, such as zinc finger nucleases, transcription activator-like effector nucleases, and most recently CRISPR technology made the production of genetically-engineered pigs easier and available to more researchers. Today, the survival of pig-to-nonhuman primate heterotopic heart, kidney, and islet xenotransplantation reached >900 days, >400 days, and >600 day, respectively. The availability of multiple-gene pigs (5 or 6 genetic modifications) and/or newer costimulation blockade agents significantly contributed to this success. Now, the field is getting ready for clinical trials with an international consensus.
    [Show full text]